Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRASOL phase III trial of mirvetuximab soravtansine versus investigator's choice chemotherapy in FRα-high platinum-resistant ovarian cancer
CTR20211628Phase 3Active
- Sponsor
- ImmunoGen
- Start
- Dec 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by ImmunoGen. Started Dec 2021; status: active.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20211628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211628.